First Patient Dosed in Ph 1 Trial for ONC-841 for Solid Tumors
“Dosing the first patient in this first-in-human trial for ONC-841 marks an important step for our SIGLEC program which holds promise to treat a range of malignancies,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4. “Targeting a novel SIGLEC10 immune checkpoint, ONC-841 is designed to block tumor evasion of the immune system by activating anti-tumor immunity within the tumor microenvironment. We are very excited at the broad therapeutic potential of ONC-841 and look forward to initial Phase 1 data in 2025.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib